Literature DB >> 8517508

Background infusion with patient-controlled analgesia: effect on postoperative oxyhaemoglobin saturation and pain control.

A W Russell1, H Owen, A H Ilsley, M T Kluger, J L Plummer.   

Abstract

The aim of this study was to determine whether the addition of a background infusion (BI) to patient-controlled analgesia (PCA) would lead to significantly improved pain control or poorer oxyhaemoglobin saturation (SpO2) after gynaecological surgery. Sixty-two patients were studied for 24 hours postoperatively; pain scores and morphine dose were recorded hourly, SpO2 was recorded every 10 seconds. Administration of the BI resulted in a significant increase in total morphine dose received although there was no difference in the severity of postoperative desaturation between the therapies. Despite the increased morphine dose pain scores also were similar in the two groups. Addition of a BI at 1 mg/hr did not confer any advantage over PCA alone and is not recommended when PCA is used in this patient group.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517508     DOI: 10.1177/0310057X9302100207

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  2 in total

Review 1.  Enhanced recovery pathways in thoracic surgery from Italian VATS Group: perioperative analgesia protocols.

Authors:  Federico Piccioni; Matteo Segat; Stefano Falini; Marzia Umari; Olga Putina; Lucio Cavaliere; Riccardo Ragazzi; Domenico Massullo; Marco Taurchini; Carlo Del Naja; Andrea Droghetti
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

2.  Effect of Fentanyl-Based Intravenous Patient-Controlled Analgesia with and without Basal Infusion on Postoperative Opioid Consumption and Opioid-Related Side Effects: A Retrospective Cohort Study.

Authors:  Haesun Jung; Kook Hyun Lee; YoungHyun Jeong; Kang Hee Lee; Susie Yoon; Won Ho Kim; Ho-Jin Lee
Journal:  J Pain Res       Date:  2020-11-24       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.